BOSTON, April 3, 2017 /PRNewswire/ -- BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced seven poster presentations showing promising preclinical data. This data reflects the impact of BERG's leading product candidate, BPM 31510, to augment immune responses and potentially improve outcomes of patients suffering from glioblastoma multiforme (GBM), pancreatic cancer, and other metabolic cancers. The research was guided by BERG's Interrogative Biology® platform and is being presented at the next annual meeting of the American Association for Cancer Research (AACR). This meeting is being held from April 1-5, 2017 in Washington, D.C.
"These insights into the mechanism of action of BPM 31510 provide further validation for its clinical potential to preferentially treat patients with highly metabolic tumors, like pancreatic cancer and GBM," said Niven R. Narain, co-founder, president and chief executive officer of BERG. "We are encouraged by the findings presented at AACR, especially in areas such as immuno-oncology, where novel methods to boost the immune system have the potential to significantly improve patient response and outcomes. In addition, our innovative platform's identification of novel biomarkers in the prostate has the potential to select patients that will mostly likely respond to treatment."
The seven abstract titles will be presented on the following dates and times:
Monday: April 3, 2017
- 8:00-12:00 (Abstract 1680/Posterboard 28): BPM 31510 Mediates T-cell Activation and Viability: Evidence of an Immune-metabolic Mechanism
- 8:00-12:00 (Abstract 1497/Posterboard 12): BPM 31510 Modulates Mitochondrial Complex Activity to Influence Oxidative Stress in Effectuating Cell Death in Multiple Cancers
- 1:00-5:00 (Abstract 2769/Posterboard 1): Project Survival: Prospective Clinical Study Utilizing Multi-omics and Artificial Intelligence to Discover Novel Molecular Markers for Detection, Stratification, and Outcome in Pancreatic Cancer
Tuesday: April 4, 2017
- 8:00-12:00 (Abstract 3826/Posterboard 22): Clinical Validation of a Serum Protein Panel (FLNA, FLNB, and KRT19) for Diagnosis and Prognosis of Prostate Cancer
- 1:00-5:00 (Abstract 4067/Posterboard 7): BPM31510, a Clinical-Stage Metabolic Modulator, Demonstrates Therapeutic Efficacy in an In Vivo C6 Rat Glioma Model and Synergizes with Temozolomide
- 1:00-5:00 (Abstract 4645/Posterboard 6): A Serum Multi-omics Signature for Enhancing Prostate Cancer Diagnosis and Prognosis
Wednesday: April 5, 2017
- 8:00-12:00 (Abstract 5576/Posterboard 8): BPM 31510: a Clinical-Stage Candidate Demonstrates Potent Anti-tumor Effect in an Immune-competent Syngeneic Pancreatic Cancer Model
At AACR (Booth 3424), BERG will be demonstrating the capabilities of the company's Interrogative Biology® platform. Its unbiased, algorithm-based approach guides the discovery, development and clinical evaluation of product candidates to create the next generation of drugs and diagnostics. BPM 31510 is one of the first cancer drug candidates guided in development by artificial intelligence. This product candidate may normalize cell metabolism by shifting the cells' energy utilization so they undergo natural cell death. Data from preclinical and human trials indicates that treatment with BPM 31510 as a single agent potentially leads to tumor regression, and that anti-tumor activity increases in combination with chemotherapy agents.
BERG is a clinical-stage company disrupting and re-defining the approach to drug discovery, research and development through its Interrogative Biology® platform. Its platform identifies therapies and biomarkers by applying algorithm- and probability-based artificial intelligence to analyze large numbers of patients' genotypic, phenotypic and other characteristics. BERG's platform operates at the intersection of biology, technology and artificial intelligence analytics and integrates many data characteristics regarding patients' lifestyles, demographics and biology. BERG believes this allows the company to better understand patients' disease profiles and consequently to identify and reveal molecular signatures to guide and accelerate product candidate selection and development. By identifying biomarkers and patient characteristics that are unique to the disease state, BERG is able to identify novel therapeutic product candidates and develop companion diagnostics to enhance specificity in its drug development process. BERG has leveraged its Interrogative Biology® platform to develop a robust pipeline of therapeutic product candidates and diagnostics in cancer, diabetes and neurology. Its platform has the potential to provide:
- physicians with actionable data to recommend efficient and safe treatment pathways;
- insurance companies with health economics analyses to develop more relevant formulary; and
- governments with a data ecosystem for modeling the healthcare needs of their populations.
For additional information, please visit www.BERGhealth.com.
CONTACT: Lisa Rivero, Ogilvy, 617-761-6746
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/berg-announces-bpm-31510-data-presentations-at-2017-aacr-in-immuno-oncology-glioblastoma-mutiforme-pancreatic-cancers-and-novel-prostate-cancer-biomarker-panel-300433281.html